Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies.

Find People
Find Research
Overview
Tutorials
FAQs
Edit My PROFILE
Login to PROFILES

Contact Us
If you have any questions or feedback please contact us.

Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies.

Almhanna K, Kalebic T, Cruz C, Faris JE, Ryan DP, Jung J, Wyant T, Fasanmade AA, Messersmith W, Rodon J. Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies. Clin Cancer Res. 2016 Oct 15; 22(20):5049-5057.

View in: PubMed

subject areas

Adenocarcinoma
Adult
Aged
Antibodies, Monoclonal
Antineoplastic Agents
Dose-Response Relationship, Drug
Female
Gastrointestinal Neoplasms
Guanylate Cyclase
Humans
Immunoconjugates
Male
Maximum Tolerated Dose
Middle Aged
Oligopeptides

authors with profiles

Wells Alton Messersmith

Contact Us
CCTSI
About CCTSI
CCTSI Affiliated Institutions
National CTSA Consortium